Biontech SE cash flow statement

In fiscal 2025, Biontech SE's operations generated $516m of cash; it spent $198m on capital projects, leaving free cash flow of $318m.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biontech SE: cash flow statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−0.1	−0.1	−0.2	−0.0	1.1	14.3	5.8	0.2	0.5
Stock-based pay	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1
Capital spending	0.0	0.0	0.0	0.1	0.2	0.3	0.3	0.3	0.2
Free cash flow	−0.1	−0.1	−0.3	−0.1	0.9	14.0	5.5	−0.1	0.3
Free cash flow after stock pay	−0.1	−0.1	−0.3	−0.1	0.8	13.8	5.5	−0.2	0.2
Dividends paid	—	—	—	0.0	0.0	0.5	0.0	0.0	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BNTX vs UTHR BMRN vs BNTX BNTX vs NBIX BNTX vs NTRA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biontech SE's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biontech SE.